Host: Monte Jade West, Chinese Bioscience Association
Date: Wednesday, September 19, 2018
Time: 6:30-9:00PM
(Registration starts at 6:30PM; Program starts at 7PM)
Location: ITRI International, 2870 Zanker Road, Suite 140, San Jose, CA 95134
Moderator: Dr. Cynthia Shen (沈忻) - CFP™, CIMA™, First Vice President, Financial Advisor, Morgan Stanley Speakers: -Dr. Keith Cheung (張靖嵐) - Research Scientist, AbVision; Secretory of Chinese Bioscience Association Title: Immunotherapy: Harnessing Our Immune System to Fight Cancer
-Dr. Curtis Lin (林峻任) - Senior Scientist, AbVision; Chinese Bioscience Association
Title: Technology-Based therapeutic strategies-Gene Editing and Cell Therapies
-Dr. Minggui Pan (潘明桂) - Oncologist, Kaiser Permanente; VP of New Hope Chinese Cancer Care Foundation Title: Immunotherapy and Cancer: Current State and Future Outlook
Registration: Online registration is required. Free.
Light dinner and water will be provided.
Introduction:
“免疫療法”和“基因編輯“是當今生物科技領域中最令人感到興奮的話題。這兩項生物技術的發展為人類帶來很大的影響；醫學界更因此改變了許多疾病的傳統治療方式，其中，最引人矚目的便是癌症醫療，且許多藥物臨床實驗都有十分穩步的進展。在今次的玉山小聚，三位在製藥和醫學領域的專家將深入淺出，帶給大家在生技和醫學治療結合的新契機。
人工智慧、大數據、自動化應用以及先進電腦運算技術已不停地刺激醫學的發展，並將持續扮演非常重要的角色。正因如此，玉山科技協會和華人生物科技協會聯手舉行這場熱門論壇，歡迎各領域的朋友一同來參與，彼此學習當前最具突破性的科技及它如何影響人類醫學治療的進步！
Immunotherapy and gene editing are two of the most exciting topics in biotechnology today. Together, they represent powerful, highly targeted alternatives to traditional treatments of many diseases, most notably cancer. Many clinical trials for drugs developed with these technologies are currently in progress. At this event, three leading experts will give an accessible overview of these recent advancements.
Automation, AI, big data and other advanced computing technologies have been instrumental in pushing these efforts forward and will continue to play key roles in their development, which is why Monte Jade and CBA invite people from all disciplines to come learn more about the breakthroughs in these fields.
First Talk Abstract by Dr. Curtis Lin (林峻任)
Title: Technology-Based Therapeutic Strategies-Gene Editing and Cell Therapies
Gene mutations are the cause of many debilitating diseases, including cancers, diabetes, and neurodegenerative diseases like Parkinson’s. In recent years, thanks to technological advances across many fields, our ability to sequence genes and decipher massive amounts of genomic information has sped up dramatically -- greatly improving our ability to study these mutations. This greater understanding, combined with new, state-of-the-art gene editing technology, has opened the door to gene therapies that can specifically target and correct defective genes. In this talk, I will explore how the study of biology has evolved over time, the basics of gene editing technology, and some of the most exciting new applications.
Second Talk Abstract by Dr. Keith Cheung (張靖嵐)
Title: Immunotherapy: Harnessing Our Immune System to Fight Cancer
Immunotherapies have shown promising potential by harnessing the power of our own immune systems to fight disease, especially cancer. They have recently drawn a lot of attention from both the pharmaceutical industry as well as the public, driven by a number of recent clinical successes such checkpoint inhibitors like Keytruda and cancer-targeting monoclonal antibodies like Rituxan. In this talk, I will introduce the concept of immunotherapy and the latest strategies in therapeutic design. I will also address the challenges immunotherapy faces and how they can be overcome.
Third Talk Abstract by Dr. Minggui Pan (潘明桂)
Title: Immunotherapy and Cancer: Current State and Future Outlook
1. Immunotherapy has been shown to be effective in many types of cancer, but not effective still in many types of cancer.
2. There are multiple types of immunotherapy for cancer using different technology and targeting different aspects of cancer vulnerabilities.
3. Immunotherapy is the most promising therapy for cancer and more effective immunotherapy methods and drugs are being developed in many countries and by many companies.
Speaker bio:
Dr. Cynthia Shen (沈忻)
Cynthia has more than 20 years of experience in wealth management. Prior to entering the financial securities industry, Cynthia worked in the Silicon Valley tech industry managing technical staff for Tymshare/Tymnet. Cynthia received her Bachelors of Arts from Australian National University and her Doctor of Philosophy in Biotechnology from State University of New York.
Dr. Keith Cheung (張靖嵐)
Keith Cheung, Ph.D. is a research scientist at AbVision focusing on immunotherapy early development. Prior to AbVision, he worked in the protein expression group at BioVision. He received his Ph.D. at the University of California, Los Angles in Biochemistry and Molecular Biology. Prior to that, he received his M.S. and B.S. at the University of California, San Diego.
Dr. Curtis Lin (林峻任)
Curtis Lin, Ph.D. is the Senior Scientist at AbVision Inc, a startup company focusing on cancer immunotherapy. Dr. Lin previous served as the Scientist in Research and Quality Control at SanBio Inc, where he was responsible for the establishment of next-generation sequencing platform and data analysis pipelines to support stem cell therapy development. Dr. Lin completed his postdoctoral fellowship in Systems Biology at the University of Texas MD Anderson Cancer Center and focused on research of tumor initiation and combination therapies. Dr. Lin received his Ph.D. in Biochemistry and Cell Biology from Rice University, Master in Biochemical Sciences from National Taiwan University, and Bachelor in Chemistry from National Cheng Kung University.
Dr. Minggui Pan (潘明桂)
Dr. Minggui Pan is chief of department of oncology and hematology. He joined Kaiser Permanente in 2002 after he finished the fellowship training at Stanford. He specializes in soft tissue and bone sarcoma and chair the soft tissue and bone sarcoma program for Kaiser Permanente Northern California. He also volunteers at the Veterans Healthcare System at Palo Alto to care for veterans with cancer as a staff attending physician and teach oncology fellows in training. He is also a clinical assistant professor (affiliated) at Stanford University School of Medicine. He has authored more than 40 scientific papers in cancer and stem cell research, many of them in high quality peer-reviewed journals such as Developmental Cell, Nature Review Clinical Oncology, Journal of Immunology, Proceedings of National Academy of Sciences USA, and others. He presented research results in the meetings of American Society of Clinical Oncology (ASCO) and the San Antonio Breast Cancer Symposium. He is currently conducting research in sarcoma and in other types of malignancies as well as immunotherapy of cancer.